Norton Cancer Institute, St. Matthews

Clinical research site in Louisville, Kentucky · Norton Cancer Institute - St. Matthews, 3991 Dutchmans Ln #405, Louisville, KY 40207 · (502) 899-3366 · Website

As of July 2026, 13 paid clinical trials are recruiting at Norton Cancer Institute, St. Matthews in Louisville, Kentucky. Active studies at this site cover conditions such as Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Norton Cancer Institute, St. Matthews (13)

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

for Lymphoma, Large B-Cell, Diffuse

71 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06890884·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

for Follicular Lymphoma (FL)

32 locations incl. Fresno

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT06191744·Phase 3·Recruiting·Listed Jan 2024

Apply to this trial

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

for Diffuse Large B-Cell Lymphoma

46 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06717347·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

for Epithelial Ovarian Cancer

65 locations incl. Birmingham

Sponsor: AbbVie

Sex: Female·Age: 18+

Code: NCT06890338·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

for DLBCL

23 locations incl. Glendale

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT05139017·Phase 2, Phase 3·Recruiting·Listed Dec 2021

Apply to this trial

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

for Cervical Cancer

92 locations incl. Phoenix

Sponsor: Pfizer

Sex: Female·Age: 18+

Code: NCT06952660·Phase 4·Recruiting·Listed May 2025

Apply to this trial

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

for Myelodysplastic Syndrome

42 locations incl. Duarte

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT04227847·Phase 1·Recruiting·Listed Jan 2020

Apply to this trial

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

for Acute Myeloid Leukemia

44 locations incl. Phoenix

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT05735184·Phase 1·Recruiting·Listed Feb 2023

Apply to this trial

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

for Multiple Myeloma (MM)

20 locations incl. Gilbert

Sponsor: C4 Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07280013·Phase 1·Recruiting·Listed Dec 2025

Apply to this trial

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

for Ovarian Cancer

21 locations incl. Birmingham

Sponsor: Regeneron Pharmaceuticals

Sex: Female·Age: 18+

Code: NCT06787612·Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

for Systemic Lupus Erythematosus (With and Without Nephritis)

13 locations incl. Phoenix

Sponsor: Allogene Therapeutics

Sex: All·Age: 18 - 69

Code: NCT07085104·Phase 1·Recruiting·Listed Jul 2025

Apply to this trial

A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL

for Indolent B-Cell Non-Hodgkin Lymphoma

1 location in Louisville

Sponsor: BioInvent International AB

Sex: All·Age: 18+

Code: NCT03571568·Phase 1, Phase 2·Recruiting·Listed Jun 2018

Apply to this trial

A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas

for CLL / SLL

4 locations incl. Louisville

Sponsor: Lomond Therapeutics Holdings, Inc.

Sex: All·Age: 18+

Code: NCT06708897·Phase 1·Recruiting·Listed Nov 2024

Apply to this trial

More research sites in Louisville

University of Louisville (65 trials)
The James Graham Brown Cancer Center at University of Louisville (38 trials)
UofL Health Medical Center Northeast (35 trials)
Norton Cancer Institute (34 trials)
Norton Children's Hospital (33 trials)
Baptist Health Louisville (21 trials)
University of Louisville Hospital (13 trials)
Norton Healthcare (9 trials)
Gastroenterology Health Partners (7 trials)
Robley Rex VA Medical Center (6 trials)

Explore more

Paid clinical trials in Louisville, KY · Kentucky clinical trials